Dr. Newman received her Ph.D. in medicinal chemistry from the Medical College of Virginia, where she designed, synthesized and behaviorally evaluated novel amphetamine analogues. During postdoctoral training at NIDDK, she extending her experience with opiate total synthesis and also developed PET ligands for opioid receptor imaging. After a short tenure at Walter Reed Army Institute of Research, she initiated a Medicinal Chemistry Program at NIDA, in Baltimore. Her research focuses on the design and synthesis of molecular tools to elucidate drug-receptor interactions in the brain and induce changes at the protein level to affect behavior. Dr. Newman is currently studying the roles of the dopamine and serotonin transporters, the dopamine D2 receptor family, and mGluR5 in addiction, aiming to develop medications for treatment.
http://irp.drugabuse.gov/Newman.php